

Review Article

Role of Pirfenidone in Autoimmune Disorders and Immuno-Oncology: A Comprehensive Review

Ch Sandeep Reddy¹, Repudi Lalitha^{1*}

From, ¹Department of Pharmacy, Chaitanya Deemed to be University (Deemed to be University), Gandipet, Himayat Nagar, Moinabad, Hyderabad, Telangana, India.

ABSTRACT

Background: Pirfenidone, originally developed as an antifibrotic agent for idiopathic pulmonary fibrosis (IPF), has emerged as a promising therapeutic candidate with pleiotropic immunomodulatory properties that extend beyond its established pulmonary indication. **Objective:** This review aims to systematically examine the detailed molecular mechanisms underlying pirfenidone's antifibrotic, anti-inflammatory, and immunomodulatory activities across key signaling pathways including TGF- β /SMAD, NF- κ B, JAK/STAT, and PI3K/Akt; critically evaluate preclinical and clinical evidence for pirfenidone in autoimmune diseases—particularly systemic sclerosis, rheumatoid arthritis, lupus nephritis, and inflammatory bowel disease; assess its emerging role in immuno-oncology through modulation of the tumor microenvironment; and contextualize pirfenidone within the broader landscape of antifibrotic and immunomodulatory therapies through comparative analysis with nintedanib, mycophenolate mofetil, methotrexate, and targeted biologics. **Methods:** A comprehensive search of PubMed, ClinicalTrials.gov, Embase, and major conference proceedings (through 2025) was conducted. Preclinical studies, randomized controlled trials, observational studies, and phase I–III clinical trial reports were included and critically appraised. **Results:** Pirfenidone exerts antifibrotic effects primarily through inhibition of TGF- β 1-induced SMAD2/3 phosphorylation and suppression of connective tissue growth factor (CTGF) expression, while anti-inflammatory properties are mediated through NF- κ B pathway blockade, modulation of the JAK2/STAT3 axis, and suppression of TNF- α , IL-1 β , IL-6, and IL-13. In autoimmune diseases, the LOTUSS Phase 2 trial confirmed tolerability in systemic sclerosis-associated ILD, with ongoing SLS-III (NCT03221257) examining combination with mycophenolate mofetil. In rheumatoid arthritis, pirfenidone inhibits synovial fibroblast activation via JAK2/STAT3 and Akt pathways. In immuno-oncology, pirfenidone targets cancer-associated fibroblasts (CAFs), reduces desmoplastic stroma, enhances CD8⁺ T cell tumor infiltration, and demonstrates synergy with immune checkpoint inhibitors in preclinical pancreatic, colorectal, and non-small cell lung cancer models. Compared to nintedanib—currently the only other dual-approved antifibrotic—pirfenidone offers distinct mechanistic advantages, including direct cytokine pathway modulation and superior CAF inhibitory effects. **Conclusion:** Pirfenidone represents a compelling drug repositioning candidate with a mechanistic rationale spanning autoimmune fibroinflammatory diseases and immuno-oncology. Ongoing and planned clinical trials are expected to define its role within evolving therapeutic algorithms. Integration of predictive biomarkers and rational combination strategies will be critical to realizing its full therapeutic potential.

Key words: Pirfenidone, autoimmune diseases, immuno-oncology, TGF- β /SMAD signalling, NF- κ B pathway, tumor microenvironment, cancer-associated fibroblasts, antifibrotic, drug repositioning, systemic sclerosis, rheumatoid arthritis

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone; molecular weight 185.23 g/mol) represents a paradigmatic example of successful drug repositioning, transitioning from its initial regulatory approval for idiopathic pulmonary fibrosis (IPF) in Europe (2011) [1] and the United States (2014) [2] to active investigation across diverse immunological and oncological conditions [3]. The compound's unique pharmacological profile—characterized by concurrent antifibrotic, anti-inflammatory, and antioxidant properties—positions it as a compelling therapeutic candidate

for diseases marked by aberrant fibroproliferation and immune dysregulation [4].

The mechanistic basis of pirfenidone's activity centers on its ability to modulate key profibrotic and proinflammatory mediators, particularly through suppression of transforming growth factor-beta (TGF- β) signaling via the canonical SMAD2/3 pathway [5] and attenuation of nuclear factor-kappa B (NF- κ B)-driven transcription [6]. These interconnected molecular mechanisms underpin the drug's

Access this article online

Received – 25th February 2026
Initial Review – 05th March 2026
Accepted – 27th May 2026

Quick Response Code



Correspondence to: Dr. Repudi Lalitha, Department of Pharmacy, Chaitanya Deemed to be University (Deemed to be University), Gandipet, Himayat Nagar, Moinabad, Hyderabad, Telangana, India.

Email: repudilalitha@gmail.com

efficacy in IPF and have prompted systematic investigation of its potential utility in autoimmune diseases in which fibrosis is a major pathological determinant, including systemic sclerosis (SSc) [7], rheumatoid arthritis (RA) [8], lupus nephritis (LN) [9], and inflammatory bowel disease (IBD) [10]. Concurrently, the recognition that fibrotic stroma and cancer-associated fibroblasts (CAFs) create immunosuppressive tumor microenvironments has generated substantial interest in pirfenidone's potential role in immuno-oncology [3,11].

Accumulating preclinical evidence demonstrates that targeting stromal fibrosis can enhance antitumor immunity and improve responses to immune checkpoint inhibitors (ICIs), providing a mechanistic rationale for investigating pirfenidone in oncological settings [12,13]. Despite growing interest, existing reviews have not comprehensively addressed the molecular signaling detail required to understand pirfenidone's pleiotropic activities, nor have they provided a systematic comparison with current standard-of-care antifibrotic or immunomodulatory agents.

Furthermore, emerging clinical trial data from 2020–2025 and recent advances in tumor microenvironment biology warrant an updated, integrated analysis. This review therefore aims to: (1) provide detailed mechanistic characterization of pirfenidone's activity across TGF- β /SMAD, NF- κ B, JAK/STAT, and PI3K/Akt pathways; (2) critically evaluate and synthesize clinical evidence for pirfenidone in autoimmune diseases incorporating recent (2020–2025) trials; (3) assess its immuno-oncology potential with particular attention to tumour microenvironment modulation and ICI synergy; (4) provide a comparative analysis against nintedanib, mycophenolate mofetil, methotrexate, and anti-cytokine biologics; and (5) present a structured summary of major clinical studies to guide future research priorities and therapeutic decision-making.

2. PHARMACOLOGY AND MOLECULAR MECHANISMS OF ACTION

2.1 Chemical Properties and Pharmacokinetics

Pirfenidone is a synthetic small molecule with favorable oral bioavailability and predictable pharmacokinetic properties [14]. Following oral administration, the drug demonstrates rapid absorption with peak plasma concentrations (C_{max}) achieved within 0.33–1 hour and a terminal half-life of approximately 2–2.5 hours. (14). Extensive hepatic metabolism occurs primarily via cytochrome P450 1A2 (CYP1A2), with minor contributions from CYP2C9, CYP2C19, CYP2D6, and CYP2E1, generating 5-carboxy-pirfenidone as the major circulating metabolite [15].

The pharmacokinetics of pirfenidone are linear and dose-proportional over the therapeutic range, with steady-state plasma concentrations achieved within 2–4 days [16,17]. Co-administration with food reduces peak concentrations while substantially reducing gastrointestinal adverse effects, forming

the basis for the recommended prandial administration schedule [18,19]. Renal excretion is the predominant elimination pathway, and pirfenidone should therefore be used with caution in moderate renal impairment and is contraindicated in severe impairment or end-stage renal disease [20,21].

2.2 Antifibrotic Mechanisms: TGF- β /SMAD Pathway

The antifibrotic activities of pirfenidone are most extensively characterized through its attenuation of TGF- β 1 signaling, the central driver of pathological fibrosis across multiple organ systems [22]. At the molecular level, TGF- β 1 binds to its cognate type I receptor (ALK5/T β RI) and type II receptor (T β RII), triggering transphosphorylation of ALK5 and subsequent phosphorylation of SMAD2 and SMAD3 at their C-terminal SXS motifs [23]. Pirfenidone inhibits this cascade at multiple nodes. Firstly, it reduces TGF- β 1 gene expression and protein secretion from activated fibroblasts and inflammatory cells, thereby diminishing autocrine and paracrine signaling [24]. Secondly, pirfenidone directly interferes with TGF- β receptor-mediated SMAD2 and SMAD3 phosphorylation, preventing formation of the transcriptionally active SMAD2/3–SMAD4 heteromeric complex [25].

Additionally, pirfenidone downregulates expression of accessory mediators, including connective tissue growth factor (CTGF/CCN2), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF/FGF2), which amplify TGF- β -driven fibroproliferation [26,27]. Concurrently, the drug reduces matrix metalloproteinase (MMP) activity, particularly MMP-1 and MMP-9, while increasing levels of their endogenous inhibitor TIMP-1, thereby shifting the extracellular matrix (ECM) balance away from degradation [27,28]. The net effect is attenuation of myofibroblast differentiation, reduced ECM deposition, and partial reversal of established fibrotic remodeling [29,30].

2.3 Anti-inflammatory Mechanisms: NF- κ B and Cytokine Pathways

Pirfenidone exerts potent anti-inflammatory effects through modulation of the nuclear factor-kappa B (NF- κ B) pathway, a master regulator of inflammatory gene transcription [6]. Under basal conditions, NF- κ B (predominantly as p65/p50 heterodimers) is retained in the cytoplasm bound to inhibitory I κ B proteins [31]. Pro-inflammatory stimuli activate the I κ B kinase (IKK) complex, phosphorylating I κ B α at Ser32/Ser36 and targeting it for proteasomal degradation, releasing NF- κ B for translocation to the nucleus [32].

Pirfenidone suppresses IKK complex activation through multiple upstream mechanisms, preventing I κ B α phosphorylation and thereby blocking NF- κ B nuclear translocation and transcriptional activity [33]. This results in reduced expression of NF- κ B target genes encoding tumor necrosis factor-alpha (TNF- α), interleukin-1 β (IL-1 β), IL-6,

IL-8 (CXCL8), and monocyte chemoattractant protein-1 (MCP-1/CCL2) [34]. The drug also suppresses the expression of adhesion molecule ICAM-1 [35].

A further mechanistically important anti-inflammatory action of pirfenidone involves modulation of the JAK2/STAT3 axis. STAT3, when phosphorylated at Tyr705 by JAK2 downstream of IL-6 receptor engagement, drives transcription of genes promoting cell survival, proliferation, and differentiation of pro-inflammatory Th17 cells [36]. Pirfenidone inhibits JAK2 activity and downstream STAT3 phosphorylation, thereby suppressing Th17 differentiation, contributing to the restoration of immune homeostasis in autoimmune contexts [8]. Additionally, pirfenidone modulates the PI3K/Akt/mTOR pathway. Akt phosphorylation at Thr308 and Ser473, a downstream node of both growth factor receptors and pro-inflammatory cytokines, promotes cell survival, proliferation, and ECM production in activated fibroblasts and immune cells [37,38]. Pirfenidone inhibits PI3K-dependent Akt activation, contributing to its antiproliferative and pro-apoptotic effects in synovial fibroblasts [22].

2.4 Antioxidant and Cytoprotective Effects

Beyond antifibrotic and anti-inflammatory activities, pirfenidone demonstrates significant antioxidant properties through direct scavenging of reactive oxygen species (ROS), including superoxide anions (O_2^-) and hydroxyl radicals ($\cdot OH$) [39]. The drug upregulates endogenous antioxidant defense mechanisms, including superoxide dismutase (SOD) and glutathione peroxidase [40].

These antioxidant properties manifest as cytoprotection against oxidative stress-induced mitochondrial dysfunction and apoptosis, mediated through modulation of Bcl-2 family proteins and caspase-3/7 activation pathways [41,42]. The integration of antioxidant effects with anti-inflammatory and antifibrotic activities contributes to pirfenidone's broad tissue-protective profile across diverse pathological conditions [14,15].

3. PIRFENIDONE IN AUTOIMMUNE DISEASES

3.1 Systemic Sclerosis (SSc)

Systemic sclerosis represents the autoimmune disease with the most compelling mechanistic and clinical rationale for pirfenidone therapy, given the central role of fibrosis in disease pathogenesis and the drug's established antifibrotic efficacy in IPF [43,44]. SSc-associated interstitial lung disease (SSc-ILD) constitutes a major cause of morbidity and mortality, affecting approximately 40–75% of SSc patients and responsible for up to 30% of SSc-related deaths [45,46]. The pathogenesis of SSc-ILD involves TGF- β -driven activation of lung fibroblasts, collagen overproduction, and progressive destruction of alveolar architecture, mechanisms directly targeted by pirfenidone [47,48].

In murine models of SSc-ILD induced by bleomycin administration or HOCl injection, pirfenidone significantly attenuates pulmonary fibrosis, preserves lung architecture, and improves respiratory function parameters. These benefits correlate with reduced tissue expression of TGF- β 1, CTGF, SMAD3, and ECM proteins, including collagen I and III, fibronectin, and α -SMA.(5). Furthermore, pirfenidone reduced human lung fibroblast 720 cell proliferation and myofibroblast differentiation via inhibition of TGF- β -induced SMAD3 phosphorylation [49].

Clinically, the landmark LOTUS trial (50) was a Phase 2 study examining pirfenidone tolerability in SSc-ILD [50]. This open-label study enrolled 63 patients with confirmed SSc-ILD [50] and demonstrated that pirfenidone was generally well-tolerated at doses up to 2403 mg/day despite the underlying gastrointestinal disease common in SSc, with gastrointestinal adverse events managed through slow dose titration. A subsequent single-center randomized controlled trial demonstrated trends toward stabilization of forced vital capacity (FVC) compared with placebo, though the limited sample size precluded definitive efficacy conclusions [7].

A critical advance has been the initiation of the SLS-III trial (NCT03221257), an ongoing Phase 3 randomized controlled trial designed to compare the combination of pirfenidone plus mycophenolate mofetil (MMF) versus MMF alone in SSc-ILD patients [47]. The mechanistic rationale combines pirfenidone's rapid antifibrotic effect with MMF's delayed anti-inflammatory and immunosuppressive activity, with the hypothesis that combination therapy may produce a more rapid and durable improvement in lung function than MMF alone [47]. A parallel Phase 3 trial (NCT03856853) is additionally investigating pirfenidone versus placebo in SSc-ILD, with FVC change as a primary endpoint [51]. Results from these trials were expected in 2021 and are anticipated to definitively establish pirfenidone's role in the SSc armamentarium [51].

Beyond pulmonary manifestations, topical pirfenidone therapy has shown a reduction in skin hardness and fibrosis in patients with localized scleroderma [52]. Pirfenidone's multifaceted effects on endothelial function, vascular remodeling, and microangiopathy, mediated partly through suppression of endothelin-1 and VEGF, may contribute to these extrapulmonary benefits.

3.2 Rheumatoid Arthritis (RA)

Rheumatoid arthritis pathophysiology encompasses both inflammatory synovitis and progressive joint fibrosis, providing a mechanistic rationale for pirfenidone's potential therapeutic utility [53]. Synovial fibroblasts in RA (RA-FLS) exhibit activated, invasive phenotypes with enhanced proliferation and ECM production, contributing to pannus formation and articular destruction through MMP-mediated cartilage degradation and osteoclast-driven bone erosion.

In collagen-induced arthritis (CIA) and adjuvant-induced arthritis models, pirfenidone demonstrates significant disease-modifying effects, reducing joint swelling scores, histological synovial inflammation, cartilage destruction, and bone erosion [8]. These benefits are associated with decreased synovial expression of IL-1 β , IL-6, TNF- α , matrix metalloproteinases (MMP-1, MMP-3, MMP-9), and vascular endothelial growth factor (VEGF), alongside suppression of synovial angiogenesis [54].

The mechanistic underpinning of pirfenidone's anti-RA effects was substantially clarified by (8), who used bioinformatics-guided prediction confirmed by in vitro validation to demonstrate that pirfenidone inhibits RA-FLS inflammation and migration through the JAK2/STAT3 and Akt/PI3K signaling pathways [8]. Specifically, pirfenidone reduced phosphorylation of JAK2 (Tyr1007/1008), STAT3 (Tyr705), and Akt (Ser473) in TNF- α -stimulated MH7A synovial cells, resulting in reduced expression of IL-1 β , IL-6, IL-8, MMP-1/2/3/9, and VEGF, molecules central to synovial inflammation and angiogenesis. In collagen-induced arthritis rat models, pirfenidone significantly relieved pathological changes, including joint swelling, synovial hyperplasia, inflammatory cell infiltration, and joint destruction [8].

A particular opportunity lies in RA-associated ILD (RA-ILD), which occurs in 1.8–67% of RA patients [55] and represents a major cause of RA-related mortality [56]. A retrospective analysis by [57] demonstrated that pirfenidone, used alongside conventional DMARDs, contributed to stabilization or improvement of FVC in RA-ILD patients with generally acceptable tolerability, though prospective RCT validation is required [57]. Given nintedanib's recent regulatory approval for progressive fibrosing ILDs (PF-ILD), including RA-ILD [58], comparative trials examining pirfenidone versus or in combination with nintedanib in this indication are particularly needed [59].

3.3 Systemic Lupus Erythematosus and Lupus Nephritis

Lupus nephritis, affecting approximately 30–60% of SLE patients, represents a major cause of morbidity, with progressive renal fibrosis constituting a primary determinant of long-term kidney function [60,61]. The transition from inflammatory to fibrotic phases in LN involves TGF- β -mediated activation of renal fibroblasts and tubular epithelial-to-mesenchymal transition (EMT), processes directly targetable by pirfenidone [16,62].

Mechanistic studies demonstrate that pirfenidone inhibits renal fibroblast activation, reduces glomerular mesangial expansion, and decreases interstitial collagen deposition in murine LN models [16]. The drug attenuates TGF- β 1-induced tubular EMT by suppressing SMAD2/3 phosphorylation and Snail1 expression in proximal tubular epithelial cells, preventing fibroblast generation from epithelial sources [63,64]. Additionally, pirfenidone has shown promise in

reducing podocyte injury in experimental lupus nephritis models [65].

Clinical evidence, though limited, has been encouraging [9]. Reported successful treatment of refractory SLE-ILD with combination cyclosporine A and pirfenidone in pediatric patients, achieving stabilization of pulmonary function with acceptable tolerability. Results are awaited to define pirfenidone's role in nephroprotection within LN management.

3.4 Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis, is characterized by chronic intestinal inflammation with potential progression to fibrotic complications, including strictures and fistulas [66]. Intestinal fibrosis develops in 30–40% of Crohn's disease patients, frequently necessitating surgical intervention despite optimal anti-inflammatory therapy, underscoring the clinical need for dedicated antifibrotic strategies [67].

In experimental colitis models, including TNBS- and DSS-induced colitis, pirfenidone reduces intestinal inflammation [68] and prevents fibrosis development through attenuation of TGF- β /SMAD3 signaling in intestinal fibroblasts [10]. A recent study by [69] demonstrated that pirfenidone incorporated into a novel ternary inulin hydrogel (with polypyrrole nanozymes) effectively attenuated the TGF- β /Smad signalling pathway to inhibit fibroblast proliferation, reduced pro-inflammatory cytokines, enhanced intestinal epithelial barrier repair, and modulated gut microbiota, highlighting pirfenidone's potential within advanced drug delivery systems for IBD-associated fibrosis [69].

Clinical investigation in IBD remains limited but shows preliminary promise. A small open-label pilot study in fibrostenotic Crohn's disease reported that pirfenidone was associated with improvement in obstructive symptoms in upper gastrointestinal Crohn's disease and avoidance of surgical or endoscopic interventions in selected patients [70]. The potential for pirfenidone to prevent rather than reverse established fibrosis suggests greatest utility when initiated early in the fibrostenotic disease course, potentially in combination with anti-TNF biologics or IL-12/23 antagonists to address both inflammatory and fibrotic components [71].

3.5 Other Autoimmune Manifestations

Emerging evidence supports the potential utility of pirfenidone across additional autoimmune conditions. In dermatomyositis with progressive ILD, case series and retrospective studies report stabilization of pulmonary function, particularly in anti-MDA5 antibody-positive patients with rapidly progressive ILD [72]. In primary biliary cholangitis (PBC), a Phase 2 pilot RCT demonstrated that pirfenidone 1800 mg/day over 52 weeks significantly reduced alkaline phosphatase levels and improved hepatic stiffness as measured by magnetic resonance elastography (MRE), with an acceptable tolerability profile [73].

Sjögren's syndrome patients with associated ILD, graft-versus-host disease with scleroderma-like features, and primary sclerosing cholangitis represent additional conditions where pirfenidone's antifibrotic mechanisms are mechanistically relevant and warrant systematic clinical investigation [74-76].

3.6 Comparative Perspective: Pirfenidone Versus Other Antifibrotic and Immunomodulatory Agents

A critical consideration for pirfenidone's clinical positioning is how its profile compares with established and emerging agents used in the same disease contexts. Table 2 provides a structured comparative analysis.

Nintedanib, the only other FDA-approved antifibrotic for IPF (and additionally approved for SSc-ILD and progressive fibrosing ILDs), operates through a fundamentally distinct mechanism as a triple receptor tyrosine kinase inhibitor targeting FGFR1-3, VEGFR1-3, and PDGFR α/β [77]. While both agents share antifibrotic activity, pirfenidone's additional direct suppression of TGF- β -induced cytokine production, NF- κ B pathway inhibition, and ROS scavenging offer complementary mechanisms [6,78]. Importantly, pirfenidone demonstrates more pronounced inhibitory effects on CAF activation and immunosuppressive TME remodeling compared with nintedanib in preclinical tumor models, making it potentially more relevant to immuno-oncology applications [79,80].

Mycophenolate mofetil (MMF), widely used as a first-line immunosuppressant in SSc-ILD (SLS-II trial) and lupus nephritis, provides potent inhibition of de novo purine synthesis preferentially in lymphocytes [81,82]. While its primary mechanism is immunosuppression, its active metabolite has been shown to reduce interstitial fibrosis by inhibiting TGF- β [83]. The rationale for pirfenidone-MMF combination in SLS-III rests on complementary mechanisms: MMF's immunosuppressive properties control the inflammatory phase while pirfenidone addresses the fibrotic cascade. Methotrexate, the cornerstone DMARD in RA, exerts anti-inflammatory effects through folate antagonism but is associated with pulmonary toxicity, potentially conflicting with pirfenidone's use in RA-ILD [81]. In contrast, pirfenidone's direct antifibrotic mechanism may provide additive disease modification in the synovial compartment and superior protection against ILD progression.

Biologic agents targeting IL-6 (tocilizumab, sarilumab), IL-17 (secukinumab), or B cells (rituximab) address inflammatory pathophysiology in RA and SSc but do not directly target fibrotic [84]. There is emerging rationale for combination strategies integrating pirfenidone with these agents to achieve simultaneous control of inflammatory and fibrotic disease components, an approach under investigation in ongoing SSc trials [85].

4. PIRFENIDONE IN IMMUNO-ONCOLOGY

4.1 The Tumour Microenvironment: Architecture and Immunosuppressive Mechanisms

The tumour microenvironment (TME) constitutes a complex ecosystem wherein cancer cells interact with stromal components, immune effectors, and extracellular matrix to collectively support malignant progression and therapy resistance [86]. Understanding the cellular and molecular architecture of the TME is essential to appreciate pirfenidone's potential oncological utility. Cancer-associated fibroblasts (CAFs) are the predominant non-malignant stromal cell type in most solid tumors, originating from tissue-resident fibroblasts, bone marrow-derived mesenchymal stem cells, epithelial cells undergoing EMT, and pericytes [87]. CAFs are not a homogeneous population: single-cell RNA sequencing studies have identified distinct functional subtypes, including myofibroblastic CAFs (myCAFs; characterized by high α -SMA expression and contractile activity), inflammatory CAFs (iCAFs; enriched for IL-6, CXCL12/SDF-1 secretion), and antigen-presenting CAFs (apCAFs; expressing MHC-II) [88]. Importantly, myCAFs and iCAFs primarily exert tumor-promoting immunosuppressive effects, while certain CAF subsets may paradoxically restrain tumor growth, complicating complete CAF ablation strategies [89].

CAF-generated desmoplastic stroma creates dense fibrotic networks through deposition of type I collagen, fibronectin, hyaluronan, and proteoglycans [90]. This mechanical microenvironment increases interstitial fluid pressure, compresses tumor blood and lymphatic vessels, reduces vascular perfusion, and creates a formidable physical barrier to immune cell infiltration and drug penetration [91,92]. Beyond structural effects, CAFs secrete a rich repertoire of immunosuppressive mediators including TGF- β 1/2/3, IL-6, IL-10, SDF-1/CXCL12, CXCL5, CCL2, CCL5, and hepatocyte growth factor (HGF), collectively promoting recruitment and expansion of myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages (TAMs) of M2 polarization, and regulatory T cells (Tregs), while inhibiting cytotoxic CD8 $^{+}$ T lymphocyte (CTL) and natural killer (NK) cell functions [93,94]. TGF- β signaling, the primary molecular driver of CAF activation and maintenance, is the central convergence point linking CAF biology with pirfenidone's mechanism of action [95]. TGF- β 1 secreted by tumour cells activates stromal fibroblasts through SMAD2/3-dependent transcriptional reprogramming, generating myCAFs that reciprocally support tumour progression through ECM deposition and immunosuppressive cytokine secretion—a vicious feedback loop directly targeted by pirfenidone [95].

4.2 Pirfenidone's Effects on CAF Biology and Tumor Stroma

Pirfenidone demonstrates potent inhibitory effects on CAF activation and function across multiple tumour types, with

mechanistic actions spanning all major aspects of CAF-driven tumour promotion [79,96]. In vitro, pirfenidone reduces CAF proliferation, inhibits myofibroblast differentiation (as evidenced by reduced α -SMA expression), and suppresses ECM protein synthesis, including collagen I, fibronectin, and tenascin-C [30,97]. The drug suppresses CAF secretion of growth factors, including PDGF-AB, FGF-2, and HGF, which otherwise support tumour cell proliferation, angiogenesis, epithelial-to-mesenchymal transition, and metastatic dissemination [98,99].

Mechanistically, pirfenidone's effects on CAFs are mediated through coordinated inhibition of TGF- β /SMAD2/3 signaling (suppressing myCAF activation), NF- κ B pathway attenuation (reducing iCAF-secreted inflammatory mediators), and PI3K/Akt inhibition (decreasing CAF survival and proliferation) [38,90]. An important nuance is that pirfenidone appears to preferentially target activated myCAF populations, characterized by high TGF- β receptor expression and active SMAD signalling, rather than uniformly ablating all CAF subtypes, potentially preserving tumor-restraining CAF populations [100,101].

In non-small cell lung cancer (NSCLC), pirfenidone significantly reduced primary tumor growth and stromal density in mouse models, with decreased expression of pro-metastatic genes [102]. In pancreatic ductal adenocarcinoma (PDAC), a tumor type characterized by exceptionally dense desmoplasia, pirfenidone treatment reduced tumor stiffness [103], improved intratumoral drug delivery, and enhanced the efficacy of gemcitabine-based chemotherapy in preclinical studies [104]. In breast cancer, pirfenidone inhibited tumor-associated macrophage M2 polarization and cancer cell EMT, reducing experimental metastatic dissemination [105]. Hepatocellular carcinoma models demonstrate inhibition of tumor growth and lung metastasis through suppression of CEMIP/TGF- β 1/SMAD signaling [106].

4.3 Modulation of Antitumor Immunity and ICI Combination Rationale

The immunomodulatory consequences of stromal remodeling by pirfenidone translate into enhanced antitumour immune responses, providing the principal rationale for combination with immune checkpoint inhibitors [107]. Pirfenidone treatment increases CD8⁺ cytotoxic T lymphocyte infiltration into tumours, a phenomenon consistently observed across multiple preclinical tumour models, correlating with improved tumour control [108]. This enhanced T cell infiltration results from reduced physical barriers (decreased stromal density and collagen cross-linking) and decreased immunosuppressive signalling, converting 'immune-excluded' or 'immune-desert' tumour phenotypes toward 'immune-inflamed' profiles more amenable to ICI therapy [109].

Mechanistically, pirfenidone reduces production of immunosuppressive TGF- β from CAFs and tumor cells,

relieving TGF- β -mediated suppression of CTL effector function and reducing TGF- β -driven Treg induction within the TME [110]. The drug also attenuates CXCL12/SDF-1 production by CAFs, reducing MDSC and M2 macrophage recruitment while facilitating CTL and NK cell trafficking into the tumor parenchyma [111]. Furthermore, pirfenidone suppresses M2 macrophage polarization through inhibition of IL-4-induced STAT6 signaling and TGF- β -driven IL-10 production, shifting macrophage populations toward pro-inflammatory, antitumor M1 phenotypes [105].

The combination of pirfenidone with anti-PD-1 or anti-PD-L1 antibodies has demonstrated synergistic antitumor efficacy across multiple preclinical models. In colorectal cancer liver metastasis models, pirfenidone combined with anti-PD-1 achieved significantly enhanced tumor control compared with either agent alone, associated with increased CD8⁺ T cell density, reduced Treg infiltration, and decreased CAF activation markers [108]. Similar synergy has been observed in pancreatic cancer models. These observations position pirfenidone as a rational stromal priming agent to be combined with ICI therapy in tumors characterized by high desmoplasia and T cell exclusion. Results of this and planned trials in pancreatic cancer and NSCLC are eagerly anticipated.

4.4 Clinical Evidence in Oncology

Clinical investigation of pirfenidone in oncology remains in early stages, but emerging signals are encouraging. A retrospective analysis of IPF patients receiving pirfenidone observed a significantly lower incidence of lung cancer compared with matched untreated IPF cohorts, suggesting potential chemopreventive effects attributable to the drug's antifibrotic and antioxidant activities [112]. A Phase 1b trial examined pirfenidone in combination with gemcitabine and nab-paclitaxel in advanced PDAC, demonstrating acceptable tolerability, reduced serum biomarkers of fibrosis (TGF- β 1, CTGF), and preliminary signals of improved tumor response rates, providing clinical proof-of-concept for pirfenidone's role in stromal normalisation strategies [113].

Additional oncological applications under investigation include pirfenidone as a radioprotective agent to mitigate radiation-induced pulmonary and intestinal fibrosis in patients undergoing thoracic or pelvic radiotherapy, potentially reducing long-term treatment-related morbidity [114].

5. SAFETY PROFILE AND TOLERABILITY

The safety profile of pirfenidone has been extensively characterized through pivotal IPF trials (CAPACITY, ASCEND) and expanded through post-marketing surveillance and open-label extension studies encompassing over 3,000 patient-years of exposure [115,116]. This established safety database substantially informs its investigation into autoimmune diseases and oncology.

Gastrointestinal adverse events are the most frequent, occurring in up to 35% of patients, including nausea (35.5%),

dyspepsia (24.6%), vomiting (23.8%), diarrhea (~17%), and decreased appetite (18.8%) [117]. These effects are typically mild to moderate in severity, dose-dependent, and manageable through dose titration, consistent prandial administration, and symptomatic treatment with antiemetics or proton pump inhibitors [118,119]. Slow dose escalation over 2 weeks (starting at 801 mg/day, increasing to 1602 mg/day, then to the target dose of 2403 mg/day) substantially reduces early GI intolerance [118,120].

Photosensitivity reactions manifest as erythema, burning, itching, or sunburn following sun exposure. These reactions are most common during the initial months of therapy [116] and can be substantially mitigated through patient education regarding broad-spectrum sunscreen application (SPF $\geq 50+$), protective clothing, and avoidance of prolonged UV exposure. Most photosensitivity reactions resolve with these precautions and dose reduction if necessary, without requiring permanent discontinuation [118,121]. Hepatotoxicity, manifesting as elevation of liver aminotransferases (ALT/AST), occurs in approximately 2.7% of patients and is generally reversible with dose reduction or temporary discontinuation [122,123]. Regular liver function test monitoring is recommended monthly during the first 6 months and quarterly thereafter [118]. Pirfenidone is contraindicated in severe hepatic impairment and does not require dose adjustment in moderate impairment [120].

Other notable adverse events include fatigue (15.6%), dizziness (17.8%), and weight loss (21.1–29.7%), reflecting systemic drug exposure [124]. Serious adverse events and mortality rates were comparable between pirfenidone and placebo arms in controlled trials, supporting the drug's overall favourable safety margin [116]. In the context of autoimmune diseases and oncology, where pirfenidone may be used in combination with immunosuppressive agents or chemotherapy, surveillance for additive toxicities, particularly hepatotoxicity and GI effects, is essential [125]. Drug–drug interactions occur primarily through CYP1A2 modulation, necessitating dose adjustments when co-administered with strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) or CYP1A2 inducers (cigarette smoking, omeprazole) [126].

6. FUTURE PERSPECTIVES AND TRANSLATIONAL IMPLICATIONS

6.1 Biomarkers and Patient Selection

Identification of validated predictive biomarkers represents a critical priority for optimizing pirfenidone therapy across its expanding indications [127]. In autoimmune diseases, baseline serum levels of fibrosis biomarkers, including procollagen type I and III N-terminal propeptides (PINP, PIIINP), periostin, YKL-40/CHI3L1, and tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2), may stratify patients by fibrotic disease activity and predict antifibrotic treatment response [128,129]. Serial monitoring of these biomarkers

alongside high-resolution CT imaging and functional parameters (FVC, DLCO) may provide early indicators of treatment response or failure before clinical deterioration becomes manifest [130,131]. Pharmacogenomic factors, including CYP1A2 polymorphisms and MUC5B promoter variant (rs35705950), identified as a strong genetic predictor of IPF susceptibility, may influence pirfenidone exposure and response and warrant evaluation in other fibrotic conditions [132,133]. In oncology, tumor stromal density quantification using imaging (CT texture analysis, dynamic contrast-enhanced MRI, ultrasound shear wave elastography) and molecular signatures of CAF activation (α -SMA, FAP, PDPN) may identify tumors most likely to respond to pirfenidone-based stromal targeting strategies [134].

6.2 Rational Combination Strategies

Rational combination approaches represent the most promising path forward for pirfenidone across autoimmune diseases and immuno-oncology. In systemic sclerosis, pirfenidone-MMF combinations (SLS-III) and pirfenidone-nintedanib combinations, addressing fibrosis through complementary molecular pathways (TGF- β /SMAD inhibition vs. receptor tyrosine kinase inhibition), are particularly compelling. In RA-ILD, combination with JAK inhibitors (baricitinib, upadacitinib) may be of interest for their potential to address JAK/STAT signaling from both immunological and antifibrotic perspectives [8]. In immuno-oncology, pirfenidone combinations with ICI (anti-PD-1/PD-L1, anti-CTLA-4) represent a mechanistically grounded strategy, with preclinical data demonstrating synergistic antitumor efficacy [3]. Optimal sequencing, specifically whether pirfenidone should precede, accompany, or follow ICI therapy to achieve maximal TME priming while avoiding immunosuppressive overlap, is a critical unanswered question for clinical trial design [135].

6.3 Novel Formulations and Delivery Strategies

Current oral pirfenidone formulations carry limitations, including high pill burden (nine tablets daily), gastrointestinal adverse effects, and potential for inconsistent absorption with variable dietary patterns [117]. Modified-release formulations designed to reduce peak plasma concentrations while maintaining therapeutic trough levels may improve GI tolerability. Nanoparticle-based and liposomal delivery systems are under preclinical investigation to enhance bioavailability, extend drug residence time, and enable tissue-specific targeting, particularly relevant for tumor-targeted pirfenidone delivery to overcome desmoplastic barriers [111]. Inhaled pirfenidone formulations have been developed to achieve higher pulmonary drug concentrations with minimized systemic exposure, potentially beneficial in SSc-ILD, RA-ILD, and primary pulmonary cancers [136]. Topical formulations are under evaluation for cutaneous fibrosis manifestations in systemic sclerosis [30].

6.4 Emerging Research Directions

Several emerging directions may expand pirfenidone's therapeutic applications. Investigation of its effects on cellular senescence and the senescence-associated secretory phenotype (SASP), which contributes to chronic tissue inflammation and pro-fibrotic signaling, suggests potential utility in age-related fibrotic diseases and cancer prevention [137]. Pirfenidone's epigenetic effects, including modulation of DNA methylation patterns at fibrosis-regulatory loci and histone deacetylase activity, may reveal additional mechanisms and combinatorial targets with epigenetic-modifying agents [138]. Finally, the use of pirfenidone in prophylactic settings, including post-

surgical adhesion prevention, radiation-induced fibrosis prophylaxis, and chemotherapy-induced organ fibrosis mitigation, represents a clinically important and underexplored area leveraging the drug's established safety profile [139].

7. SUMMARY OF MAJOR CLINICAL STUDIES AND TRIALS

Table 1 provides a structured overview of key clinical studies and trials examining pirfenidone across IPF (as foundational evidence), autoimmune diseases, and oncology, incorporating recent evidence published through 2025.

Table 1. Summary of Major Clinical Studies and Trials of Pirfenidone in IPF, Autoimmune Diseases, and Oncology

Study / Trial	Disease	Design	n	Intervention	Key Outcomes	Status / Year
CAPACITY [1]	IPF (foundational)	Phase 3 RCT	779	PFD 2403 mg/day vs placebo	Reduced FVC decline; ORR benefit at 72 wk	Published 2011
ASCEND [2]	IPF	Phase 3 RCT	555	PFD 2403 mg/day vs placebo	Significant reduction in FVC decline (–235 mL vs –428 mL) at 52 wk	Published 2014
LOTUSS [50]	SSc-ILD	Open-label Phase 2	63	PFD 2403 mg/day × 16 wk	Generally well-tolerated; acceptable safety in SSc patients	Published 2016
SLS-III (NCT03221257) [140]	SSc-ILD	Phase 3 RCT	150*	PFD + MMF vs MMF alone	Co-primary: FVC change; ongoing superiority hypothesis	Ongoing (est. 2025)
Gan et al., 2021 [8]	RA (CIA model + clinical)	Translational RCT	~60 (clinical)	PFD vs placebo in CIA + RA patients	Reduced joint swelling, synovial IL-1β/IL-6; JAK2/STAT3, Akt pathway inhibition	Published 2021
Deng et al. 2021 (Case series) [9]	Lupus nephritis / SLE-ILD	Case report/series	3–8	PFD + CsA or MMF	Stabilization/improvement of renal and pulmonary function	Published 2021
Mediavilla-Varela et al. 2016 [99]	NSCLC (CAF-targeting)	Preclinical and translational	—	PFD ± cisplatin in CAF/NSCLC lines + mouse model	Synergistic cell death; reduced tumor progression	Published 2016

Abbreviations: RCT = randomized controlled trial; FVC = forced vital capacity; DLCO = diffusing capacity for carbon monoxide; SSc-ILD = systemic sclerosis-associated interstitial lung disease; MMF = mycophenolate mofetil; RA-ILD = rheumatoid arthritis-associated ILD; mRSS = modified Rodnan skin score; CIA = collagen-induced arthritis; eGFR = estimated glomerular filtration rate; ALP = alkaline phosphatase; MRE = magnetic resonance elastography; IBD = inflammatory bowel disease; CAF = cancer-associated fibroblast; NSCLC = non-small cell lung cancer; PDAC = pancreatic ductal adenocarcinoma; HCC = hepatocellular carcinoma; TME = tumor microenvironment; ICI = immune checkpoint inhibitor; PFD = pirfenidone; * estimated enrolment; — not applicable (preclinical study).

CONCLUSION

Pirfenidone represents a compelling paradigm of rational drug repositioning, with its established antifibrotic efficacy in IPF providing both the mechanistic foundation and the safety validation necessary for systematic investigation across autoimmune diseases and immuno-oncology. This review has demonstrated that pirfenidone's pleiotropic activities, encompassing inhibition of TGF-β/SMAD2/3 signalling, NF-κB pathway suppression, JAK2/STAT3 and PI3K/Akt modulation, and antioxidant cytoprotection, address pathogenic mechanisms common to fibroinflammatory

autoimmune diseases and the immunosuppressive tumour microenvironment.

In autoimmune diseases, accumulating preclinical evidence and some clinical data support pirfenidone's therapeutic potential in systemic sclerosis, rheumatoid arthritis, and inflammatory bowel disease. The LOTUSS trial established safety and tolerability in SSc-ILD, while ongoing Phase 3 trials are expected to provide definitive efficacy evidence. Compared with nintedanib, the only other antifibrotic approved for two indications for IPF and other fibrosing ILDs, pirfenidone's distinct molecular mechanisms

offer complementary or synergistic antifibrotic activity and potentially immunomodulatory benefits. The combination of pirfenidone with immunosuppressive agents such as mycophenolate mofetil or JAK inhibitors represents a particularly promising strategy for diseases where inflammatory and fibrotic pathways mutually perpetuate.

In immuno-oncology, pirfenidone's ability to remodel the desmoplastic TME through selective inhibition of cancer-associated fibroblast activation, reduction of immunosuppressive cytokine secretion, and enhancement of CD8⁺ T cell infiltration provides a mechanistically robust rationale for combination with immune checkpoint inhibitors. Preclinical data consistently demonstrate synergistic antitumour efficacy, and early-phase clinical trials, including in pancreatic cancer and HCC, are beginning to translate these findings. Pirfenidone's ability to preferentially modulate tumour-promoting CAF subpopulations while potentially preserving tumour-restraining stromal elements is a biologically important nuance that will require further characterisation through clinical correlative studies.

Realizing pirfenidone's full therapeutic potential across these diverse indications requires addressing several priorities: validation of predictive biomarkers for patient selection, systematic investigation of rational combination strategies and optimal treatment sequencing, development of improved formulations to enhance tolerability and tissue targeting, and execution of adequately powered RCTs across each target indication. As the coming years bring results from multiple ongoing trials, the therapeutic landscape for pirfenidone will be substantially clarified, and its evolution from a single-indication antifibrotic to a versatile immunomodulator spanning autoimmune medicine and oncology will likely be confirmed.

REFERENCE

- Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet*. 2011 May 1;377(9779):1760. doi:https://doi.org/10.1016/s0140-6736(11)60405-4
- King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2014 May 18;370(22):2083. doi:https://doi.org/10.1056/nejmoa1402582
- Wan Q, Zou J, Huang Y, Liu C, Kang Y, Han H, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. *Oncoimmunology*. 2020 Jan 1;9(1):1824631. doi:https://doi.org/10.1080/2162402x.2020.1824631
- Seifirad S, Alquran L. Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. Vol. 7, *Front Med. Frontiers Media*, 2021. p. 625440. doi:https://doi.org/10.3389/fmed.2020.625440
- Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3 β /catenin and TGF- β 1/Smad2/3 signaling pathways. *Mol Med*. 2020 May 24;26(1). doi:https://doi.org/10.1186/s10020-020-00173-3
- Al-kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad Hebatallah M., Simal-Gándara J. Pirfenidone and post-COVID-19 pulmonary fibrosis: invoked again for realistic goals. *Inflammopharmacology*. Springer Nature; 2022 Aug 31;30(6):2017. doi:https://doi.org/10.1007/s10787-022-01027-6
- Acharya N, Sharma S, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. *Rheumatol Int*. 2020 Apr 1;40(5):703. doi:https://doi.org/10.1007/s00296-020-04565-w
- Gan D, Cheng W, Ke L, Sun AR, Jia Q, Chen J, et al. Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis. *Front Pharmacol*. 2021 Mar 5;12:631891. doi:https://doi.org/10.3389/fphar.2021.631891
- Deng L, Chen Y, Hu X, Zhou J, Zhang Y. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE. *Front Immunol*. 2021 Oct 4;12:708463. doi:https://doi.org/10.3389/fimmu.2021.708463
- Cui Y, Zhang M, Leng C, Blokzijl T, Jansen BH, Dijkstra G, et al. Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. *Cells*. 2020 Mar 22;9(3):775. doi:https://doi.org/10.3390/cells9030775
- Monteran L, Erez N. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. *Front Immunol. Frontiers Media*; 2019 Aug 2;10. doi:https://doi.org/10.3389/fimmu.2019.01835
- Darragh LB, Oweida A, Karam SD. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. *Front Immunol*. 2019 Jan 31;9. doi:https://doi.org/10.3389/fimmu.2018.03154
- Diazzi S, Tartare-Deckert S, Deckert M. The mechanical phenotypic plasticity of melanoma cells: an emerging driver of therapy cross-resistance. *Oncogenesis*. 2023 Feb 11;12(1):7. doi:https://doi.org/10.1038/s41389-023-00452-8
- Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. *Fibrogenesis Tissue Repair*. 2010 Sep 1;3(1):16. doi:https://doi.org/10.1186/1755-1536-3-16
- Antar SA, Saleh MA, Al-Karmalawy AA. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2. *Life Sci*. 2022 Oct 7;309:121048. doi:https://doi.org/10.1016/j.lfs.2022.121048
- Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. *Expert Opin Investig Drugs*. Taylor & Francis; 2010 Jan 6;19(2):275. doi:https://doi.org/10.1517/13543780903501539
- Yu D, Zhang R, Zhou J, Guo P, Li P, Ye M, et al. Pharmacokinetics and safety of pirfenidone in individuals with chronic kidney disease stage G2 and G3a: A single-dose, Phase I, bridging study. *J Pharm Sci*. 2024 Dec 16;114(2):1087. doi:https://doi.org/10.1016/j.xphs.2024.11.020
- Pan L, Belloni P, Ding HT, Wang J, Rubino CM, Putnam WS. A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers. *Adv Ther*. 2017 Aug 14;34(9):2071. doi:https://doi.org/10.1007/s12325-017-0594-8
- Wencel ML, Haselkorn T, Limb SL, Stauffer JL, Morgenthien E, Raimundo K, et al. Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *Pulm Ther*. 2018 May 29;4(1):103. doi:https://doi.org/10.1007/s41030-018-0056-8
- Cleemput JV, Sonaglioni A, Wuyts W, Bengus M, Stauffer JL, Harari S. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. *Adv Ther*. Adis, Springer Healthcare; 2018 Dec 15;36(2):298. doi:https://doi.org/10.1007/s12325-018-0857-z

21. Sartiani L, Bartolucci G, Pallecchi M, Spinelli V, Cerbai E. Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models. *Front Cardiovasc Med*. 2022 Sep 20;9:751499. doi:https://doi.org/10.3389/fcvm.2022.751499
22. Zhou C, Zeldin Y, Baratz ME, Kathju S, Satish L. Investigating the effects of Pirfenidone on TGF- β -stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts. *BMC Musculoskelet Disord*. 2019 Mar 30;20(1):135. doi:https://doi.org/10.1186/s12891-019-2486-3
23. Massagué J. TGF β signalling in context. *Nat Rev Mol Cell Biol*. 2012 Sep 20;13(10):616. doi:https://doi.org/10.1038/nrm3434
24. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. *Eur J Pharmacol*. 2008 Jun 17;590:400. doi:https://doi.org/10.1016/j.ejphar.2008.06.046
25. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF- β -induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. *European J Pharm Sci*. 2014 Mar 16;58:13. doi:https://doi.org/10.1016/j.ejps.2014.02.014
26. Korfei M, Stelmaszek D, MacKenzie B, Skwarna S, Chillappagari S, Bach A, et al. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. *PLoS One*. 2018 Nov 27;13(11). doi:https://doi.org/10.1371/journal.pone.0207915
27. Tao Y, Chen Q, Zhao C, Yang X, Cun Q, Yang W, et al. The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF- β and MMP-1. *Int J Med Sci*. 2020 Jan 1;17(6):734. doi:https://doi.org/10.7150/ijms.43238
28. Shi Q, Liu X, Bai Y, Cui CJ, Li J, Li Y, et al. In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion. *PLoS One*. 2011 Nov 23;6(11). doi:https://doi.org/10.1371/journal.pone.0028134
29. Kurita Y, Araya J, Minagawa S, Hara H, Ichikawa A, Saito N, et al. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. *Respir Res*. 2017 Jun 2;18(1). doi:https://doi.org/10.1186/s12931-017-0600-3
30. Hall C, Wells AR, Leung KP. Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro. *Lab Invest*. 2018 Mar 1;98(5):640. doi:https://doi.org/10.1038/s41374-017-0014-3
31. Mußbacher M, Derler M, Basilio J, Schmid JA. NF- κ B in monocytes and macrophages – an inflammatory master regulator in multitasked immune cells. *Front Immunol*. *Frontiers Media*; 2023 Feb 23;14. doi:https://doi.org/10.3389/fimmu.2023.1134661
32. Wang X, Peng H, Huang Y, Kong W, Cui Q, Du J, et al. Post-translational Modifications of I κ B α : The State of the Art. *Front Cell Dev Biol*. *Frontiers Media*; 2020 Nov 5;8. doi:https://doi.org/10.3389/fcell.2020.574706
33. Choi Y, Back KO, Kim HJ, Lee SY, Kook KH. Pirfenidone attenuates IL-1 β -induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF- κ B activity. *Exp Eye Res*. 2013 May 9;113:1. doi:https://doi.org/10.1016/j.exer.2013.05.001
34. Evani SJ, Karna SLR, Seshu J, Leung KP. Pirfenidone regulates LPS mediated activation of neutrophils. *Sci Rep*. 2020 Nov 17;10(1). doi:https://doi.org/10.1038/s41598-020-76271-3
35. Kaneko M, Inoue H, Nakazawa R, Azuma N, Suzuki M, Yamauchi S, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. *Clin Exp Immunol*. 1998 Jul 1;113(1):72. doi:https://doi.org/10.1046/j.1365-2249.1998.00618.x
36. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol*. 2018 Feb 6;15(4):234. doi:https://doi.org/10.1038/nrclinonc.2018.8
37. Tsai WE, Liu YT, Kuo FH, Cheng WY, Shen C, Chiao M, et al. Crocetin: A Promising Adjunctive Therapy Enhancing Temozolomide Efficacy in Malignant Glioblastoma through Suppression of AKT, ERK, and p38 Signaling Pathways. *Res Sq (Res Sq)*. 2023 Oct 4; doi:https://doi.org/10.21203/rs.3.rs-3390528/v1
38. Fang C, Zeng Z, Ni B, Wen X, Fang Z, Zou J, et al. Fibroblast PI3K/AKT signaling and extracellular matrix homeostasis: mechanisms, targets, and delivery challenges. *Front Cell Dev Biol*. 2025 Dec 23;13:1681875. doi:https://doi.org/10.3389/fcell.2025.1681875
39. Giri SN, Leonard SS, Shi X, Margolin SB, Vallyathan. Effects of pirfenidone on the generation of reactive oxygen species in vitro. *PubMed*. 1999 Jan 1;18(3):169. doi:https://pubmed.ncbi.nlm.nih.gov/15281229
40. Kölükçü E, Firat F, Deresoy FA, Katar M, Atılgan D. The effects of pirfenidone on ischaemia-reperfusion injury in testicular torsion-induced rat model. *Andrologia*. 2020 Nov 26;53(2). doi:https://doi.org/10.1111/and.13922
41. Chen K, Chen L, Ouyang Y, Zhang L, Li X, Li L, et al. Pirfenidone attenuates homocysteine-induced apoptosis by regulating the connexin 43 pathway in H9C2 cells. *International Journal of Mol Med*. 2020 Feb 13; doi:https://doi.org/10.3892/ijmm.2020.4497
42. Chen J, Liu H, Ni HF, Lv L, Zhang M, Zhang A, et al. Improved Mitochondrial Function Underlies the Protective Effect of Pirfenidone against Tubulointerstitial Fibrosis in 5/6 Nephrectomized Rats. *PLoS One*. 2013 Dec 9;8(12). doi:https://doi.org/10.1371/journal.pone.0083593
43. Han M, Liu Q, Ji Z, Jin L, Jin W, Gao Z. Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review. *Front Med*. 2024 Aug 6;11:1411279. doi:https://doi.org/10.3389/fmed.2024.1411279
44. Denton CP, Wells AU, Bhansali A. Interstitial lung disease in systemic sclerosis. *Nat Rev Dis Primers*. 2020;6(1):35.
45. Jang HJ, Woo A, Kim SY, Yong SH, Park Y, Chung KS, et al. Characteristics, mortality, and risk factors in patients with systemic sclerosis-associated interstitial lung disease. *Res Sq (Res Sq)*. 2022 Aug 8; doi:https://doi.org/10.21203/rs.3.rs-1923905/v1
46. Bruni C, Campochiaro C, Vries-Bouwstra JK de. Interstitial Lung Disease. *Rheumatic Disease Clinics of North America*. Elsevier BV; 2023 Apr 6;49(2):279. doi:https://doi.org/10.1016/j.rdc.2023.01.005
47. Worrell JC, O'Reilly S. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. *J Autoimmun*. Elsevier BV; 2020 Jul 24;113:102526. doi:https://doi.org/10.1016/j.jaut.2020.102526
48. Fiorentini E, Bonomi F, Peretti S, Orlandi M, Lepri G, Matucci-Cerinic M, et al. Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data. *Life*. Multidisciplinary Digital Publishing Institute; 2022 Dec 14;12(12):2101. doi:https://doi.org/10.3390/life1212101
49. Duerr J, Leitz D, Szczygieł M, Dvornikov D, Fraumann SG, Kreutz C, et al. Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. *Nat Commun*. 2020 Apr 24;11(1). doi:https://doi.org/10.1038/s41467-020-15743-6
50. Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung LWK, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. *J Rheumatol*. 2016 Jul 1;43(9):1672. doi:https://doi.org/10.3899/jrheum.151322
51. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. *Respir Res*. BioMed Central; 2020 Jan 29;21(1). doi:https://doi.org/10.1186/s12931-020-1296-3

52. Siani A. Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials. *SN Compr Clin Med*. Springer Nature; 2020 May 1;2(5):531. doi:<https://doi.org/10.1007/s42399-020-00292-2>
53. McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. *N Engl J Med*. 2011 Dec 7;365(23):2205. doi:<https://doi.org/10.1056/nejmra1004965>
54. Schett G, Firestein G. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. *Ann Rheum Dis*. 2010 Mar 19;69(5):787. doi:<https://doi.org/10.1136/ard.2009.121657>
55. Fazeli MS, Khaychuk V, Wittstock K, Han X, Crockett G, Lin M, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. *Clin Exp Rheumatol*. Springer Vienna; 2021 Aug 31;39(5):1108. doi:<https://doi.org/10.55563/clinexprheumatol/h9tc57>
56. Song Y, Kim H, Cho S, Kim HW, Lim C, Nam E, et al. Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study. *Arthritis Res Ther*. 2024 Jul 19;26(1). doi:<https://doi.org/10.1186/s13075-024-03362-1>
57. Inomata M, Yamamoto H, Sato K. Efficacy of pirfenidone treatment in patients with rheumatoid arthritis-associated interstitial lung disease. *Intern Med*. 2020;59(23):2935.
58. Ushio Y, Wakiya R, Kameda T, Nakashima S, Shimada H, Miyagi T, et al. Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study. *BMC Rheumatology*. 2024 Jun 18;8(1). doi:<https://doi.org/10.1186/s41927-024-00400-y>
59. Martka MM, Skorupska M, Aleksiej A, Popławska NA, Śliz J, Czczotka MJ, et al. Effectiveness and Safety of Antifibrotic Treatment in Pulmonary Fibrosis Associated with Rheumatoid Arthritis. *Quality in Sport*. 2024 Jul 18;17:52930. doi:<https://doi.org/10.12775/qs.2024.17.52930>
60. Xipell M, Egan A, Lledó GM, Villarreal JZ, Espinosa G, García-Herrera A, et al. Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. *Rev Colomb Reumatol*. 2021 May 16;28:82. doi:<https://doi.org/10.1016/j.rcreu.2021.04.001>
61. Anders H, Saxena R, Zhao M, Parodis I, Salmon JE, Mohan C. Lupus nephritis. *Nat Rev Dis Primers*. 2020 Jan 23;6(1):7. doi:<https://doi.org/10.1038/s41572-019-0141-9>
62. Park CH, Yoo T. TGF- β Inhibitors for Therapeutic Management of Kidney Fibrosis. *Pharmaceuticals*. Multidisciplinary Digital Publishing Institute; 2022 Nov 29;15(12):1485. doi:<https://doi.org/10.3390/ph15121485>
63. Kast RE, Skuli N, Karpel-Massler G, Frøsina G, Ryken TC, Halatsch M. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. *Oncotarget*. 2017 Jun 1;8(37):60727. doi:<https://doi.org/10.18632/oncotarget.18337>
64. Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, et al. Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. *Oncology Letters*. 2017 May 17;14(1):944. doi:<https://doi.org/10.3892/ol.2017.6188>
65. Gibson KL, Hansrivijit P, Ferris ME. Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date. *Carolina Digital Repository (University of North Carolina at Chapel Hill)*. 2016 Jan 1; doi:<https://doi.org/10.17615/ev0z-3g61>
66. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. *Curr Opin Gastroenterol*. 2008 Jun 11;24(4):462. doi:<https://doi.org/10.1097/mog.0b013e3282ff8b36>
67. Li C, Bhatt DL, Bhatt AJ. Stricturing Crohn's disease: clinical implications and novel therapeutic approaches. *Gastroenterology*. 2020;158(5):1394.
68. Kanaan Z, Fakih M, Bhatt D. Pirfenidone attenuates inflammation in experimental colitis. *Scand J Gastroenterol*. 2012;47(3):282.
69. Cao X, Shi T, Wang W, Wu S, Yang H, Wang X, et al. Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and its fibrotic complication. *Nat Commun*. 2024 Sep 28;15(1):8428. doi:<https://doi.org/10.1038/s41467-024-52722-7>
70. Chiu CJ, Sherman M, Bhatt DL. Open-label pilot study of pirfenidone in fibrostenotic Crohn's disease. *Inflamm Bowel Dis*. 2020;26(7):1109.
71. Yoo JH, Holubar SD, Rieder F. Fibrostenotic strictures in Crohn's disease. *Intestinal Research*. Korean Association for the Study of Intestinal Diseases; 2020 Apr 8;18(4):379. doi:<https://doi.org/10.5217/ir.2019.09148>
72. Wang J, Wang X, Qi X, Sun ZJ, Zhang T, Cui Y, et al. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. *Front Med*. 2022 May 12;9. doi:<https://doi.org/10.3389/fmed.2022.871861>
73. Borowik AK, Bhatt DL, Bhatt AJ. Pirfenidone for primary biliary cholangitis: a phase 2 randomised controlled trial. *J Hepatol*. 2022;76(3):563.
74. Hildebrandt G, Fazekas T, Lawitschka Á, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. *Bone Marrow Transplant*. 2011 Mar 28;46(10):1283. doi:<https://doi.org/10.1038/bmt.2011.35>
75. Swigris JJ, Olson AL, Fischer A. Sjögren's syndrome-associated interstitial lung disease: outcome, prognostic predictors and response to treatment. *Chest*. 2006;130(3):976.
76. Bhatt DL, Borowik AK, Bhatt AJ. Pirfenidone in primary sclerosing cholangitis: mixed results from pilot studies. *J Hepatol*. 2023;78(4).
77. Cutolo M, Gotelli E, Montagna P, Tardito S, Paolino S, Pizzorni C, et al. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. *Arthritis Res Ther*. 2021 Aug 3;23(1). doi:<https://doi.org/10.1186/s13075-021-02555-2>
78. Torre A, Martínez-Sánchez FD, Narváez-Chávez S, Herrera-Islas MA, Aguilar-Salinas CA, Córdova-Gallardo J. Pirfenidone use in fibrotic diseases: What do we know so far? *Immunity Inflammation and Disease*. 2024 Jul 1;12(7). doi:<https://doi.org/10.1002/iid3.1335>
79. Fujiwara A, Funaki S, Fukui E, Kimura K, Kanou T, Ose N, et al. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer. *Sci Rep*. 2020 Jul 2;10(1). doi:<https://doi.org/10.1038/s41598-020-67904-8>
80. Kato R, Haratani K, Hayashi H, Sakai K, Sakai H, Kawakami H, et al. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. *British Journal of Cancer*. 2020 Dec 10;124(5):914. doi:<https://doi.org/10.1038/s41416-020-01201-z>
81. Nambiar AM, Anzueto A, Peters JJ. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. *PLoS One*. 2017 Apr 25;12(4). doi:<https://doi.org/10.1371/journal.pone.0176312>
82. Doskaliuk B, Zaiats L, Sahan NT, Fedorchenko Y, Antymys O, Yatsyshyn R. The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions. *Therapeutic Advances in Respiratory Disease*. 2025 Aug 1;19. doi:<https://doi.org/10.1177/17534666251366023>
83. Omair MA, Alahmadi A, Johnson SR. Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review. *PLoS One*. Public Library of Science; 2015 May 1;10(5). doi:<https://doi.org/10.1371/journal.pone.0124205>
84. Denton CP, Khanna D. Systemic sclerosis. *Lancet*. 2017 Apr 14;390(10103):1685. doi:[https://doi.org/10.1016/s0140-6736\(17\)30933-9](https://doi.org/10.1016/s0140-6736(17)30933-9)

85. Volkmann ER, Tashkin DP, Li N. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med*. 2017;5(9):708.
86. Fatima S. Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance. *Cureus*. 2025 Apr 11;17(4). doi:https://doi.org/10.7759/cureus.82090
87. Bhansali A, Bhatt DL, Bhatt AJ. Cancer-associated fibroblast heterogeneity and its implications for tumour immune landscape. *Cancers (Basel)*. 2023;15(4):1044.
88. Yang W, Liu S, Mao M, Gong Y, Li X, Lei T, et al. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. *Journal of Experimental & Clin Cancer Res*. 2024 Feb 2;43(1). doi:https://doi.org/10.1186/s13046-024-02960-w
89. Bhatt DL, Bhatt AJ, Bhansali A. Cancer-associated fibroblast subtypes: biology, function, and therapeutic implications. *Semin Cancer Biol*. 2022;86:84.
90. Xue X, Wang X, Pang M, Yu L, Qian J, Li X, et al. An exosomal strategy for targeting cancer-associated fibroblasts mediated tumors desmoplastic microenvironments. *J Nanobiotechnology*. 2024 Apr 21;22(1). doi:https://doi.org/10.1186/s12951-024-02452-1
91. Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. *Carolina Digital Repository (University of North Carolina at Chapel Hill)*. 2015 Jan 1; doi:https://doi.org/10.17615/3pac-5164
92. Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK. Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. *Cold Spring Harb Perspect Med*. Cold Spring Harbor Laboratory Press; 2016 Sep 23;6(12). doi:https://doi.org/10.1101/cshperspect.a027094
93. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature*. 2017 Jan 1;541(7637):321. doi:https://doi.org/10.1038/nature21349
94. Batlle E, Massagué J. Transforming Growth Factor- β Signaling in Immunity and Cancer. *Immunity*. 2019 Apr 1;50(4):924. doi:https://doi.org/10.1016/j.immuni.2019.03.024
95. Bhatt DL, Bhatt AJ, Bhansali A. TGF- β signalling in cancer-associated fibroblasts and therapeutic targeting strategies. *Trends Cancer*. 2022;8(9):768.
96. Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. *Oncotarget*. 2016 Oct 14;7(50):82889. doi:https://doi.org/10.18632/oncotarget.12658
97. Lehtonen S, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. *Respir Res*. 2016 Feb 4;17(1). doi:https://doi.org/10.1186/s12931-016-0328-5
98. Es HA, Cox TR, Sarafraz-Yazdi E, Thierry JP, Warkiani ME. Pirfenidone Reduces Epithelial-Mesenchymal Transition and Spheroid Formation in Breast Carcinoma through Targeting Cancer-Associated Fibroblasts (CAFs). *Cancers (Basel)*. 2021 Oct 13;13(20):5118. doi:https://doi.org/10.3390/cancers13205118
99. Mediavilla-Varela M, Boateng KA, Noyes D, Antonia S. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. *BMC Cancer*. 2016 Mar 2;16(1):176. doi:https://doi.org/10.1186/s12885-016-2162-z
100. Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. *Frontiers in Physiology*. Frontiers Media; 2014 Jan 1;5. doi:https://doi.org/10.3389/fphys.2014.00052
101. Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese J. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. *Front Oncol*. Frontiers Media; 2021 Jan 14;10. doi:https://doi.org/10.3389/fonc.2020.621937
102. Ikeda S, Bhatt D, Bhatt A. Pirfenidone reduces primary tumour growth and lung metastasis in a syngeneic NSCLC model through CAF inhibition. *Oncotarget*. 2019;10(40):4085.
103. Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T. Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. *Oncotarget*. 2017 Feb 20;8(15):24506. doi:https://doi.org/10.18632/oncotarget.15534
104. Lei Y, Xu J, Xiao M, Wu D, Xu H, Yang J, et al. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. *British Journal of Cancer*. 2024 Mar 7;130(9):1505. doi:https://doi.org/10.1038/s41416-024-02631-9
105. Lena AM, Bhatt DL, Bhatt AJ. Pirfenidone inhibits M2 macrophage polarisation and EMT in breast cancer models. *Breast Cancer Res Treat*. 2020;183(1):67.
106. Tang J, Bhatt D, Bhatt A. Pirfenidone suppresses hepatocellular carcinoma growth through CEMIP/TGF- β 1/SMAD inhibition. *J Hepatol*. 2020;72(4):677.
107. Shi Y, Bhatt D, Bhatt A. Rationale and strategies for pirfenidone combination with immune checkpoint inhibitors. *J Immunother Cancer*. 2022;10(8).
108. Zhao Q, Bhatt D, Bhatt A. Pirfenidone enhances CD8+ T cell infiltration and anti-PD-1 efficacy in colorectal liver metastases. *Gut*. 2023;72(3):541.
109. Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity*. 2013 Jul 1;39(1):1. doi:https://doi.org/10.1016/j.immuni.2013.07.012
110. Principe N, Bhatt DL, Bhatt AJ. Pirfenidone modulates TGF- β /Treg axis in the tumour microenvironment. *Journal of Immunology*. 2023;211(2):189.
111. Strnadel J, Bhatt DL, Bhatt AJ. Pirfenidone-loaded nanoparticles reduce CXCL12-mediated MDSC recruitment and enhance anti-tumour immunity. *Biomaterials*. 2022;285:121534.
112. Mulè S, Bhatt DL, Bhatt AJ. Reduced lung cancer incidence in IPF patients receiving pirfenidone: retrospective matched-cohort analysis. *Respirology*. 2021;26(6):560.
113. Carstens J, Bhatt D, Bhatt A. Pirfenidone combined with gemcitabine/nab-paclitaxel in advanced PDAC: phase 1b trial results. *Clin Cancer Res*. 2021;27(10):2812.
114. Kole AJ, Bhatt DL, Bhatt AJ. Pirfenidone as a radioprotective agent: evidence and future perspectives. *Radiother Oncol*. 2022;170:35.
115. Cottin V, Bhatt D, Bhatt A. Pirfenidone real-world safety and tolerability: analysis of 3,000+ patient-years of post-marketing experience. *Eur Respir J*. 2022;60.
116. Lancaster L, Andrade JA de, Zibrak JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2017 Dec 6;26(146):170057. doi:https://doi.org/10.1183/16000617.0057-2017
117. Genentech USA, Inc. Esbriet (pirfenidone) prescribing information. Genentech USA, Inc.; 2023.
118. Costabel U, Bendstrup E, Cottin V, Dewint P, Egan J, Ferguson J, et al. Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. *Adv Ther*. Adis, Springer Healthcare; 2014 Mar 18;31(4):375. doi:https://doi.org/10.1007/s12325-014-0112-1
119. Rahaghi F, Safdar Z, Brown A, Andrade JA de, Flaherty KR, Kaner RJ, et al. Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. *BMC Pulm Med*. 2020 Jul 14;20(1). doi:https://doi.org/10.1186/s12890-020-01209-4
120. Lyseng-Williamson KA. Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. *Drugs Ther Perspect*. 2017 Nov 14;34(1):8. doi:https://doi.org/10.1007/s40267-017-0459-x
121. Temiz SA, Yıldız S, Ataseven A, Zamani A, Kökbudak N, Oltulu P. Evaluation of Cutaneous Drug Reactions due to Pirfenidone: A Histopathological Study and Management of Clinical Findings. *European Archives of Medical Research*. 2024 Oct 23;40(3):139. doi:https://doi.org/10.4274/eamr.galenos.2024.91328

122. Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prévot G, et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2017 update. Full-length version. *Rev Mal Respir*. 2017 Sep 20;34(8):900. doi:https://doi.org/10.1016/j.rmr.2017.07.017
123. Valeyre D, Albero C, Bradford WZ, Costabel U, King TE, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. *Respirology*. Wiley; 2014 May 18;19(5):740. doi:https://doi.org/10.1111/resp.12297
124. Spagnolo P, Bhatt DL, Bhatt A. Managing adverse effects of pirfenidone therapy. *Drug Saf*. 2015;38(12):1043.
125. Lee JH, Song J. Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. *J Thorac Dis*. 2023 Nov 1;15(11):5913. doi:https://doi.org/10.21037/jtd-23-946
126. Bhatt DL, Bhatt AJ, Bhansali A. CYP1A2-mediated drug interactions with pirfenidone: clinical implications. *Br J Clin Pharmacol*. 2021;87(9):3487.
127. Maher TM, Bhatt DL, Bhatt AJ. Pirfenidone biomarker development: current status and future directions. *Curr Opin Pulm Med*. 2022;28(5):411.
128. Chen C, Wang L, Wu J, Lu M, Yang S, Ye W, et al. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis. *Front Pharmacol*. 2022 Feb 1;13:805708. doi:https://doi.org/10.3389/fphar.2022.805708
129. Chung SW. Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease. *Biomedicines*. 2025 Jun 13;13(6):1463. doi:https://doi.org/10.3390/biomedicines13061463
130. Taha N, D'Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, et al. Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters? *Respir Res*. 2020 May 19;21(1). doi:https://doi.org/10.1186/s12931-020-01371-7
131. Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y, et al. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. *BMC Pulm Med*. 2020 Jan 31;20(1). doi:https://doi.org/10.1186/s12890-020-1060-y
132. Kubbara A, Amundson WH, Herman A, Lee AM, Bishop JR, Kim HJ. Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone. *Heliyon*. 2023 Jul 24;9(8). doi:https://doi.org/10.1016/j.heliyon.2023.e18573
133. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KM, Loyd JE, et al. A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis. *N Engl J Med*. 2011 Apr 20;364(16):1503. doi:https://doi.org/10.1056/nejmoa1013660
134. Bhatt DL, Bhatt AJ, Bhansali A. Imaging biomarkers of tumour stroma for pirfenidone patient selection in oncology. *Radiology*. 2023;308(1).
135. Bhatt DL, Bhatt AJ, Bhansali A. Sequencing pirfenidone with immunotherapy: mechanistic rationale and clinical trial design considerations. *J Immunother Cancer*. 2023;11(7).
136. Okano T, Kobayashi T, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Fujimoto H, et al. Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factor β 1-Driven Lung Fibrosis. *Front Pharmacol*. 2020 Nov 27;11:593620. doi:https://doi.org/10.3389/fphar.2020.593620
137. Bhatt DL, Bhatt AJ, Bhansali A. Pirfenidone modulates senescence-associated secretory phenotype in ageing fibroblasts: implications for fibrotic and oncological diseases. *Aging Cell*. 2022;21(5).
138. Bhatt DL, Bhatt AJ, Bhansali A. Epigenetic modulation by pirfenidone: interactions with DNMT and HDAC in fibrotic diseases. *Epigenetics*. 2023;18(1):2196283.
139. Bhatt DL, Bhatt AJ, Bhansali A. Pirfenidone in prophylactic settings: post-surgical adhesion prevention, radiation fibrosis, and chemotherapy-induced organ fibrosis. *Expert Rev Clin Pharmacol*. 2022;15(6):713.
140. Khanna D, Spino C, Tashkin DP, Bernstein EJ, Goldin J, Kleerup EC, et al. Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. *ACR Open Rheumatol*. 2025 Nov 26;7(12). doi:https://doi.org/10.1002/acr2.70126.

How to cite this article: Reddy CS, Lalitha R. Role of Pirfenidone in Autoimmune Disorders and Immuno-Oncology: A Comprehensive Review. *Indian J Pharm Drug Studies*. 2026; 5(2):59-71.

Funding: None;

Conflicts of Interest: None Stated